Fertility and Sterility
Volume 93, Issue 1 , Pages 270-271 , 1 January 2010

Blood group and ovarian hyperstimulation syndrome

Received 20 May 2009 ,Revised 8 July 2009 ,Accepted 9 July 2009.

References 

  1. Shahin AY. The problem of IVF cost in developing countries: has natural cycle IVF a place?. Reprod Biomed Online. 2007;15:51–56
  2. Practice Committee of American Society for Reproductive Medicine . Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90:S188–S193
  3. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–2937
  4. Mathur R, Kailasam C, Jenkins J. Review of the evidence base strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil (Camb). 2007;10:75–85
  5. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901–907
  6. Papanikolau EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod. 2005;20:636–641
  7. Binder H, Flegel WA, Emran J, Müller A, Cupisti S, Beckmann MW, et al. Blood group A: an overseen risk factor for early-onset ovarian hyperstimulation syndrome. Reprod Biomed Online. 2008;17:185–189
  8. ÓDonnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11:343–351
  9. Bellver J, Muñoz E, Ballesteros A, Soares SR, Bosch E, Simón C, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod. 2003;18:2283–2288
  10. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–440
  11. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321–333

 J.B. has nothing to disclose. M.F. has nothing to disclose. N.G. has nothing to disclose. A.P. has nothing to disclose.

PII: S0015-0282(09)02479-0

doi: 10.1016/j.fertnstert.2009.07.983

Fertility and Sterility
Volume 93, Issue 1 , Pages 270-271 , 1 January 2010

Article Tools